Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Axitinib
Drug ID BADD_D00193
Description Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3).[L6676] Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors.[L6676] Axitinib is an indazole derivative.[A179398] It is most commonly marketed under the name Inlyta® and is available in oral formulations.
Indications and Usage Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.
Marketing Status Prescription
ATC Code L01EK01
DrugBank ID DB06626
KEGG ID D03218
MeSH ID D000077784
PubChem ID 6450551
TTD Drug ID D01ZRI
NDC Product Code 54893-0043; 68554-0088; 54893-0032; 65344-0033; 63539-044; 0069-0151; 0069-0145; 63539-026
Synonyms Axitinib | AG 013736 | AG013736 | AG-013736 | Inlyta
Chemical Information
Molecular Formula C22H18N4OS
CAS Registry Number 319460-85-0
SMILES CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)C=CC4=CC=CC=N4
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cholecystitis09.03.01.0010.003996%
Cholelithiasis09.03.01.0020.001332%Not Available
Chromaturia20.02.01.0020.001066%
Chronic obstructive pulmonary disease22.03.01.007--Not Available
Clostridium difficile colitis11.02.02.004; 07.19.01.0040.000799%Not Available
Cold sweat23.02.03.002; 08.01.03.0240.000533%Not Available
Confusional state19.13.01.001; 17.02.03.005--
Constipation07.02.02.0010.016251%
Coronary artery disease24.04.04.006; 02.02.01.001--Not Available
Coronary artery stenosis24.04.04.017; 02.02.01.0100.000533%Not Available
Cough22.02.03.001--
Deafness04.02.01.0010.001066%Not Available
Death08.04.01.0010.036487%
Dehydration14.05.05.0010.017583%
Delirium19.13.02.001--
Dementia19.20.02.001; 17.03.01.0010.002131%Not Available
Depressed level of consciousness17.02.04.002--
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Diabetes mellitus14.06.01.001; 05.06.01.001--Not Available
Diabetes mellitus inadequate control14.06.01.004; 05.06.01.0040.000533%Not Available
Diarrhoea07.02.01.0010.111093%
Diplopia17.17.01.005; 06.02.06.002--Not Available
Discomfort08.01.08.003--Not Available
Disorientation17.02.05.015; 19.13.01.002--Not Available
Disseminated intravascular coagulation24.01.01.010; 01.01.02.0020.000208%
Disturbance in attention19.21.02.002; 17.03.03.001--
Diverticulitis11.01.07.003; 07.10.02.0010.001066%Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Drug hypersensitivity10.01.01.001--Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 19 Pages